重组人血管内皮抑制素联合GP方案治疗晚期非小细胞肺癌37例临床观察

目的观察重组人血管内皮抑制素（恩度）联合GP方案治疗晚期非小细胞肺癌（NSCLC）的疗效和毒副反应。方法经病理学或细胞学检查证实的37例晚期NSCLC患者，包括鳞癌21例，腺癌16例。吉西他滨1000mg／m^2，静脉滴注，第1、8天；顺铂80mg／m^2，静脉滴注，分3d给予；恩度15mg／d，静脉滴注，第1～14天，21d为1个周期。每例患者至少完成2个周期。根据WHO疗效评定及毒副反应分级标准，观察其近期疗效、疾病进展时间及毒副反应。结果37例晚期NSCLC患者中，CR1例，PR15例，SD14例，PD7例，总有效率（CR＋PR）43．2％。中位疾病进展时间为5．2个月。毒副反应主要为血液学、消化道毒性，Ⅲ-Ⅳ度中性粒细胞减少占32．4％，Ⅲ-Ⅳ度血小板减少占20．5％，未见与化疗相关的死亡。结论恩度联合GP方案治疗晚期NSCLC近期客观疗效较高，安全性好。

Combination of recombinant human endostatin and GP in the treatment of advanced non-small cell lung cancer

Objective To observe the efficacy and safety of recombinant human endostatin injection (en-dostar) combined with GP(gemcitabine plus cisplatin)regimen in patients with advanced non- small cell lung cancer (NSCLC). Methods Thirty seven histologically confirmed advanced NSCLC patients were enrolled in the group. The patients were administered with endostar 15 mg from day 1 to 14,gemcitabine 1 000 mg/m2 day 1 and 8,cisplatin 80 mg/m2 on days devided into 1 - 3, repeated 21 days. Each patient should complete two cycles. Results 37 patients were valuable for response. One patient achieved complete response(CR), 15 partial response(PR), 14 stable disease (SD) ,and 7 were found to have disease progression(PD). The total response rate was 43.2% ,median TIP was 5.2 months. The main toxicities was leukopenia. There was no treatment-related death in this series. Conclusion En-dostar combined GP regimen was effective and safe in treatment of advanced NSCLC.